Skin Cancer Early Diagnosis and Detection Rates Increased by New App
the Cancer Therapy Advisor take:
Professors Jonathan Rees, Grant Chair of Dermatology, and Bob Fisher of the School of Informatics at the University of Edinburgh in Edinburgh, United Kingdom, have developed a digital application called Dermofit to help clinicians accurately identify benign and malignant skin lesions and growths earlier in their development.
Dermofit contains photos of various skin lesions that clinicians can use to diagnose their patients more effectively. When a practitioner clicks an image of a skin lesion of interest, the application shows other similar lesions to help practitioners differentiate between the various types of skin lesions.
According to Professor Rees, 30% of doctors will refer a patient to the hospital if the patient presents with signs of a skin lesion; however, the majority of those referred patients do not have a skin malignancy and are in no danger whatsoever. By using the application, resources and money could be saved.
Dermofit is now licensed to Simedics Limited, company specializing in digital products for the healthcare sector. The company plans to launch the application in the United Kingdom later this year with plan for global markets.
Dermofit helps clinicians accurately identify benign and malignant skin lesions.
The early diagnosis and detection rates of skin cancer has been boosted by a pioneering digital application developed at the University of Edinburgh which trains the medical profession to accurately identify malignant and benign skin lesion and skin growths at an earlier stage.
The app - named Dermofit - has now been licensed to Simedics Limited, a Yorkshire-based company specialising in digital products and publishing for the healthcare and public sector services.
Dermofit is the brainchild of Professor Jonathan Rees, Grant Chair of Dermatology at the University of Edinburgh who had the initial concept to develop a digital tool to educate GPs in order to improve skin lesion diagnosis proficiency back in 2005.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer